- Conditions
- Soft Tissue Sarcoma
- Interventions
- Palifosfamide-Tris, doxorubicin, Placebo
- Drug
- Lead sponsor
- Alaunos Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 447 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 73
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 65 more
Location Directory
Clinical trials in Rochester, Minnesota
This page shows live ClinicalTrials.gov search results for Rochester, Minnesota, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
9154
Shown on this page
12
Current sort
Recently updated
Location scope
Rochester, MN
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 925–936 of 9,154 matching trials in Rochester, MN.
Live ClinicalTrials.gov results.
Institutions in Rochester
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Melanoma
- Interventions
- Dabrafenib mesylate, Hydroxychloroquine, Placebo Administration, Trametinib dimethyl sulfoxide
- Drug
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 199
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 139 more
- Conditions
- cGVHD
- Interventions
- Non-Interventional
- Other
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 30 more
- Conditions
- Myelofibrosis
- Interventions
- SAR302503 (TG101348)
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 6
- States / cities
- La Jolla, California • Stanford, California • Boston, Massachusetts + 3 more
- Conditions
- Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV
- Interventions
- Surovatamig
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 18 Years
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 14
- States / cities
- La Jolla, California • Denver, Colorado • New Haven, Connecticut + 11 more
- Conditions
- Autosomal Dominant Polycystic Kidney Disease
- Interventions
- ABBV-CLS-628, Placebo
- Drug
- Lead sponsor
- Calico Life Sciences LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Huntington Park, California • Los Angeles, California + 34 more
- Conditions
- Primary Hyperoxaluria Type 1
- Interventions
- Not listed
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- Not listed
- Enrollment
- 207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Washington D.C., District of Columbia • Boston, Massachusetts + 5 more
- Conditions
- Aortic Aneurysm, Abdominal, Juxtarenal Aortic Aneurysm, Extent IV Thoracoabdominal, Pararenal Aneurysm
- Interventions
- Zenith Fenestrated+ Endovascular Graft in combination with the BeGraft Balloon-Expandable FEVAR Bridging Stent Graft System and Unibody2
- Device
- Lead sponsor
- Cook Research Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 27 more
- Conditions
- Multiple Myeloma
- Interventions
- Arlocabtagene Autoleucel
- Biological
- Lead sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 33 more
- Conditions
- Plexiform Neurofibroma, Neurofibromatosis Type 1 (NF1)
- Interventions
- Mirdametinib (PD-0325901) oral capsule or dispersible tablet
- Drug
- Lead sponsor
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 37 more
- Conditions
- Anaplastic Astrocytoma, Glioblastoma, Malignant Glioma
- Interventions
- Radiation Therapy, Temozolomide, Veliparib
- Radiation · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 3 Years to 25 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 145
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 111 more
- Conditions
- Multiple System Atrophy (MSA)
- Interventions
- ONO-2808, Placebo
- Drug
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 30
- States / cities
- Fountain Valley, California • Los Angeles, California • Palo Alto, California + 23 more